Contribute Try STAT+ Today

Three months ago, Effendi Ortiz-Toro resigned from Shire Pharmaceuticals (SHPG), where he worked as sales director for the Midwest region, and took a job with Ultragenyx (RARE), which also sells rare-disease drugs. A few weeks later, three regional business managers followed him out the door and also joined Ultragenyx, a scenario that Shire alleges involved stealing confidential information.

In a lawsuit filed earlier this month, Shire claimed its former employees surreptitiously conspired to take valuable lists of doctors who specialize in treating rare disorders. As a result, Shire argued, Ultragenyx quickly gained a competitive edge and Shire asked a federal court to issue a restraining order to prevent Ultragenyx from marketing a newly approved medicine for treating a rare disease called Sly syndrome.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.